Cargando…
Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells
Background: Prostate cancer is the second leading cause of cancer-related deaths in Western countries. Most patients diagnosed with advanced prostate cancer can be treated with the main treatment: androgen deprivation therapy (ADT). The androgen receptor (AR) signaling axis plays a pivotal role in t...
Autores principales: | Cui, Luwei, Liu, Ming, Lai, Shicong, Hou, Huimin, Diao, Tongxiang, Zhang, Dalei, Wang, Miao, Zhang, Yaoguang, Wang, Jianye |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556480/ https://www.ncbi.nlm.nih.gov/pubmed/31239713 http://dx.doi.org/10.2147/OTT.S193480 |
Ejemplares similares
-
Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells
por: Li, Wei, et al.
Publicado: (2018) -
Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase
por: Yu, Pan, et al.
Publicado: (2017) -
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
por: Gustavsson, Heléne, et al.
Publicado: (2010) -
Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.
por: Wolf, D. A., et al.
Publicado: (1991) -
Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling
por: TILLI, TATIANA MARTINS, et al.
Publicado: (2015)